

AHCC Trials Group

Newsletter Oct 2014

The Buzz AHCC06 Investigators' Meeting

10 July 2014, Taipei

Phase III Multi-Centre Open – Label Randomized Controlled Trial of Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (SIRveNIB)

Contents

Page 1-2

The Buzz

- AHCC06 Investigators' Meeting, 10 July 2014

Page 2

Happenings

- AHCC Trials Group Scientific Forum and General Meeting, 31 October 2014

Page 3-4

Highlights

- AHCC06 Study Status
- New Project Manager for AHCC06

AHCC Trials Group

Group Chair:

Prof Soo Khee Chee

Protocol Chair, AHCC06:

Prof Pierce Chow

Trials Group Website:

<http://www.scri.edu.sg/index.php/ahcc-trials-group>

Trial Coordinating Centre:

Greetings to all members of the AHCC Trials Group!

The AHCC06 trials held its 3rd Investigators' Meeting on 10 July 2014 at Westin Taipei, Taiwan. The meeting was attended by investigators from 17 sites and provided an opportunity for the investigators to evaluate study progress, engage in peer-to-peer discussion about common challenges and best practices, and to stimulate a creative exchange of ideas.

During the meeting, Protocol Chair, Professor Pierce Chow gave an overall study update and Project Manager, Ms Sophie Moss, shared details on the additional funding from Sirtex.

Associate Professor Chanisa Chotipanich from Chulabhorn Hospital, Thailand and Doctor Ariunaa Khasbazar from National Cancer, Mongolia shared case studies on Patient Recruitment and Retention.

The meeting ended with Prof Chow announcing the inception of the AHCC Trials Group collaborative platform with support from National Cancer Centre Singapore (NCCS) and pharmaceutical companies. This will allow the Trials Group to have regular scientific meetings on top of investigators' meetings of specific clinical trials.

It was a fruitful meeting thanks to the support of Singapore Clinical Research Institute (SCRI) and the AHCC Trials Group Organising Committee, who were integral in ensuring its success.

The investigators look forward to meeting again at the AHCC Trials Group Scientific Forum and General Meeting on 31 October 2014.

AHCC06 Investigators' Meeting 10 July 2014, Taipei



AHCC Trials Group Scientific Forum and General Meeting 31 October 2014, Singapore

Following extensive discussions with external partners, the AHCC Trials Group collaborative platform is now made possible. The aim is to establish a platform for all group members to meet and discuss relevant current issues regarding hepatocellular carcinoma (HCC). It also provides an opportunity for the group members to network and possibly collaborate on some projects. These meetings will be held bi-annually and all members, including those who are not actively participating in the current trial, would be invited to join the meeting. The inaugural meeting will take place on 31 October 2014 at the National Cancer Centre in Singapore. Prof Chow, co-founder of the AHCC Trials Group, would update the Trials Group on the AHCC06 trial. Current projects and new projects will also be discussed in the meeting.

This meeting will be held in conjunction with the AHCC Trials Group Scientific Forum. There will be notable speakers sharing on innovative studies on HCC as well as current issues regarding HCC. The Scientific Forum is open to all physicians, researchers and industry and would allow the members of the AHCC Trials Group to meet leaders in the industry.

Look out for reports on the Scientific Forum in the next Newsletter.

AHCC06 (SIRveNIB)

Phase III Multi-Centre Open-Label Randomized Control Trial of Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma

Protocol Chair: Prof Pierce Chow, NCCS, SGH and Duke-NUS

For more details on the AHCC06 trial,
please visit <http://www.sirvenib.com/>

Study Status

As of 30 September 2014, 262 patients have been randomized. This is 73% of the target enrolment. We would like to congratulate China Medical University Hospital which joined the trial on 6 April 2014, for recruiting its 1st patient in July 2014.

The trial has progressed well and the news of the additional funding is celebrated by the study team and sites. The last Investigators' Meeting was fruitful with critical feedback addressed and new ancillary studies developed. The Investigators' Meeting held in Taipei, Taiwan on 10 July 2014 updated the study teams of the progress and the direction of the trial.

The trial's second interim analysis was carried out on 27 October. The second interim analysis aims to review safety and efficacy. The result of the analysis will be shared with the team during the AHCC Trials Group General Meeting on 31 October 2014.

As the trial is more than two-thirds to completion of recruitment, we would like to thank the study teams for their continued support and hard work.

Prospective Sites

In an interesting development for the AHCC06 trial, 2 sites have expressed interest in joining the trial, namely **University Malaya Medical Centre, Malaysia** and **National Cheng Kung University Hospital, Taiwan**. The addition of these sites would aid in the recruitment numbers for AHCC06 trial and hopefully expedite the study. We look forward to the active participation of these sites.

Participating Centres:

Brunei

- The Brunei Cancer Centre

Hong Kong

- Queen Mary Hospital

Indonesia

- University of Indonesia
- Sanglah General Hospital

Korea

- Asan Medical Center
- Korea Anam University Hospital
- Seoul National University
 Bundang Hospital
- Seoul St. Mary's Hospital
- Severance Hospital

Malaysia

- Penang Adventist Hospital

Mongolia

- National Cancer Center

Myanmar

- Yangon GI & Liver Centre

New Zealand

- Auckland City Hospital

Philippines

- Makati Medical Center
- St. Luke's Medical Center
- The Medical City
- Davao Doctors Hospital

Singapore

- Khoo Teck Puat Hospital
- National Cancer Centre
- National University Hospital
- Singapore General Hospital

Taiwan

- National Taiwan University Hospital
- Chang Gung Memorial Hospital, LK
- Taipei Veterans General Hospital
- China Medical University Hospital

Thailand

- Chulabhorn Hospital

New Project Manager for AHCC06



Due to personal reasons, Ms Sophie Moss has left SCRI and returned to the United Kingdom. On behalf of the Trials Group, we would like to thank her for the outstanding leadership. The diligence and dedication demonstrated will have a major impact in guiding the team's work in future. We wish her all the best in her future endeavours.

We would also like to welcome the new project manager, Mr Xia Yu. He was a clinical research associate overseeing the Myanmar and Thailand sites for the past 2 years and working with Choice Pharma for Taiwan sites for about 1 year. He is very familiar with this study. He has a strong interest in Clinical Research and is currently pursuing a M.Sc. in Clinical Research.

Xia Yu is experienced in clinical monitoring, site coordination and management. He has worked in various investigator-initiated studies covering different phases and therapeutic areas over the past two years. With his knowledge, experience and passion, he wishes to contribute to the success of the AHCC06 trial, and bring the study to a new height. We hope everybody participating in this study will give him your fullest support.

Contact Details

For further queries, please contact the AHCC Trials Group at

Project Manager (AHCC06):

Mr Xia Yu

Email: yu.xia@scri.edu.sg

DID: (65) 6508 8314

Network Secretariat:

Ms Phang Su Ting

Email: phang.su.ting@sqh.com.sg

DID: (65) 6326 6450

Ms Lynette Lai

Email: phang.su.ting@sqh.com.sg

DID: (65) 6576 2151

Ms Rachel Choi

Email: rachel.choi.h.y@sqh.com.sg

DID: (65) 6576 7657

**Read more about all trials
under AHCC Trials Group at
<http://www.scri.edu.sg>.**

Mailing Address: 31 Biopolis Way Nanos #02-01 Singapore 138669

Acknowledgements: National Medical Research Council Singapore, SingHealth Foundation, PsiOncology, Sirtex Medical and Bayer Pharmaceutical for support of our clinical trials, past and present